@article{9b3db6c37cf24129822611c2870c55d6,
title = "A regional analysis of payer and provider views on cholesterol management: PCSK9 inhibitors as an illustrative alignment model.",
author = "Dana McCormick and Bhatt, \{Deepak L\} and Bays, \{Harold E\} and Taub, \{Pam R\} and Caldwell, \{Kim A\} and Guerin, \{Chris K\} and Jeff Steinhoff and Zahid Ahmad and Rubina Singh and Kathleen Moreo and Jeffrey Carter and Heggen, \{Cherilyn L\} and Tamar Sapir",
note = "BACKGROUND: Multiple barriers exist for appropriate use of the proprotein convertase subtilisin/kexin type 9 enzyme inhibitors (PCSK9i) in patients with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) with inadequately controlled hypercholesterolemia despite standard therapies. Among these barriers, high payer rejection rates and inadequate prior authorization (PA) documentation by providers hinder optimal use of PCSK9i.",
year = "2020",
month = nov,
day = "30",
doi = "10.18553/JMCP.2020.26.12.1517",
language = "American English",
volume = "26",
journal = "Journal of managed care \& specialty pharmacy",
number = "12",
}